Physician profile
John L Caplan
NPI 1386622769
$11,847.96
in general payments reported to CMS, 2019-2025
28 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,120 · 2020: $1,432 · 2021: $3,568 · 2022: $356 · 2023: $1,921 · 2024: $969 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,990 · Travel and Lodging: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,990.19 |
| Travel and Lodging | $381.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,878.40 | 2019-2024 | |
| Medtronic Vascular, INC. | $2,347.36 | 2019-2020 | |
| Boston Scientific Corporation | $2,269.90 | 2019-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Vigilant X4 Crt-D |
| Altathera Pharmaceuticals LLC | $1,042.75 | 2020-2024 | Sotalol Hydrochloride |
| Janssen Pharmaceuticals, INC | $575.18 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $494.69 | 2022-2025 | Assure Wcd |
| Abbott Laboratories | $451.91 | 2019-2025 | Jot Dx |
| E.R. Squibb & Sons, L.L.C. | $237.65 | 2019-2024 | Camzyos, Eliquis |
| Biotronik INC. | $233.19 | 2025 | Biomonitor |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Novocure INC. | $148.67 | 2024 | Optune |
| Amgen INC. | $144.58 | 2019-2024 | Repatha |
| Cardiva Medical, INC. | $113.96 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Medtronic, INC. | $95.67 | 2021-2022 | |
| Stereotaxis INC | $95.24 | 2023 | Niobe |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.34 | 2019-2025 | Lifevest |
| Pfizer INC. | $72.54 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $70.89 | 2019-2023 | |
| Philips North America LLC | $68.56 | 2023-2025 | Igt Devices Undivided |
| Merck Sharp & Dohme LLC | $60.53 | 2022-2024 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $28.82 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $26.29 | 2019-2020 | |
| Atricure, INC. | $23.07 | 2022 | |
| Genzyme Corporation | $20.22 | 2024 | |
| Bridgebio Pharma, INC. | $18.40 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.24 | 2024 | Jardiance |
| Novo Nordisk INC | $14.97 | 2025 | Ozempic |
| Arbor Pharmaceuticals, INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Caplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.